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Abstract Minimal inhibitory concentrations (MICs) and
minimal bactericidal concentrations (MBCs) of various
antimicrobial agents were measured against 12 strains of
Streptococcus pyogenes isolated from children with inva-
sive infections between 2003 and 2012. The patients ran-
ged in age from 1 day to 15 years, with patients younger
than 5 years, including three neonates, accounting for a
half of the patients. The disease was sepsis in four patients,
skin and soft tissue infection in three patients, retropha-
ryngeal abscess in two patients, pneumonia plus sepsis in
one patient, empyema in one patient, and pyogenic arthritis
in one patient. One patient with sepsis died, while cure
without sequelae was achieved in all the remaining
patients. When classiﬁed by type, emm1 (six strains) was
the most prevalent type, followed by emm12 (two strains).
The MIC90/MBC90 values were 0.015/0.015 lg/mL for
penicillin G, 0.03/0.03 lg/mL for ampicillin, 0.015/
0.03 lg/mL for cefotaxime, 0.03/0.03 lg/mL for ceftriax-
one, 0.008/0.008 lg/mL for panipenem, 0.008/0.008 lg/
mL for meropenem, and B0.004/B0.004 lg/mL for
doripenem, indicating the superior antimicrobial activities
of carbapenem.
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Introduction
Streptococcus pyogenes is the major causative agent for
pharyngitis and tonsillitis, but may also cause, although
relatively rarely, invasive infections such as meningitis,
sepsis, and necrotizing fasciitis. For such infections, treat-
ment with antimicrobial agents exhibiting superior activity
against S. pyogenes must be initiated immediately. Peni-
cillin agents are representative drugs used as the agents of
ﬁrst choice for infections caused by hemolytic streptococci.
However, many reports on the sensitivity of S. pyogenes to
antimicrobial agents pertain to strains isolated from patients
with pharyngitis or tonsillitis, and there are very few reports
focusing on strains isolated from patients with invasive
infections. Moreover, most of the drugs evaluated in com-
parison with the penicillins in these reports are oral anti-
microbial agents, and there are no reports on the efﬁcacy of
intravenous antimicrobial agents, carbapenems in particu-
lar, used for the treatment of invasive infections.
In order to select appropriate antimicrobial agents for
the treatment of hemolytic streptococcal infections asso-
ciated with serious symptoms, the minimal inhibitory
concentrations (MICs) and minimal bactericidal concen-
trations (MBCs) of various antimicrobial agents were
examined for S. pyogenes strains isolated from children
with invasive infections such as sepsis. Although many
reports state that severe infection is associated with speciﬁc
emm types, no results are available for children in Japan.
Therefore, we evaluated this association.
Subjects and method
A total of 12 strains of S. pyogenes isolated from children
who were examined for invasive infections at pediatric
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departments in medical institutions in Hokkaido, including
our hospital, during the 10-year period between July 2003
and June 2012 were included for this study. Severe infec-
tion with S. pyogenes was deﬁned as: (1) detection of
S. pyogenes from originally sterile sites such as blood,
cerebrospinal ﬂuid, and puncture ﬂuid and (2) while S. py-
ogenes was detected from non-sterile sites such as the skin
and pharynx, no other bacteria could be assumed to be the
cause and, furthermore, the pathology is not inconsistent
with infection due to S. pyogenes. Patients considered to
have invasive infections were those with serious symptoms
that were almost life-threatening, those requiring a surgical
procedure such as drainage and/or debridement, and those
requiring hospitalization for 2 weeks or more.
The MIC values of seven drugs (penicillin G, ampicillin,
cefotaxime, ceftriaxone, panipenem, meropenem, doripe-
nem) were measured by the broth microdilution method
[1]. For determination of the MBC, a culture suspension of
10 lL was collected from the plate on which the MIC was
measured and applied to non-selective culture media in
wells containing the drug at a concentration equal to or
greater than the MIC. After aerobic cultivation at 35C for
20–24 h, the number of colonies were counted, and the
concentration that caused a decrease in the volume of
the growing bacteria by 99.9 % or more was determined as
the MBC [2].
The Laboratory of Molecular Epidemiology for Infec-
tious Agents, Kitasato Institute of Life Sciences, was
requested to perform a determination of the emm types. At
the laboratory, M protein-coding genes were ampliﬁed by
PCR and the base sequence at the 50 terminal end of the
ampliﬁed product was determined; thereafter, that
sequence of 300 bp was transmitted to the CDC Reference
Center and the types were determined by matching with the
CDC database [3].
Results
Table 1 shows a list of patients with invasive infections
caused by S. pyogenes. The patients ranged widely in age
from 1 day to 15 years, with patients younger than 5 years,
including three neonates, accounting for half of all the
patients. None of the patients had any underlying diseases.
The disease was sepsis in four patients, skin and soft tissue
infection in three patients, retropharyngeal abscess in two
patients, pneumonia plus sepsis in one patient, empyema in
one patient, and pyogenic arthritis in one patient. None of
the patients had concurrent toxic shock syndrome. One
patient (a 15-year-old adolescent girl) with pneumonia plus
sepsis died of shock. The most prevalent emm type was
emm1 (six strains; 50.0 %), followed by emm12 (two
strains; 16.7 %), while emm3, emm4, emm6, and emm28
were recognized in one strain each.
Figures 1 and 2 show the distributions of the MICs and
MBCs for each drug, and Table 2 shows the MIC90 and
MBC90 values. The drug with the most potent antibacterial
activity was doripenem, with MICs and MBCs of 0.004 lg/
mL or less for all the strains. This drug was followed in
antibacterial potency by panipenem, the MIC and MBC of
which were determined to be 0.004 lg/mL or less and
0.008 lg/mL for six strains each. For meropenem, both the
Table 1 Characteristics of children with severe infection due to Streptococcus pyogenes
Case number Age Type of emm Diagnosis Isolated Antibiotic therapy Prognosis
1 1 day 6 Pyothorax Pleural ﬂuid ABPC 11 days Cure
2 4 days 1 Sepsis Blood ABPC 9 days Cure
3 7 days 1 Sepsis Blood ABPC 11 days Cure
4 1 year 12 Cellulitis Skin swab ABPC 7 days Cure
5 3 years 12 Sepsis Blood ABPC 14 days Cure
6 3 years 1 Sepsis Blood ABPC 14 days Cure
7 5 years 28 Arthritis Synovial ﬂuid CEZ 7 days Cure
8a 5 years 4 Retropharyngeal abscess Pharyngeal swab IPM/CS 2 days Cure
9 7 years 3 Cellulitis Skin exudate IPM/CS 7 days Cure
10 11 years 1 Erysipelas Pharyngeal swab ABPC 7 days Cure
11 11 years 1 Retropharyngeal abscess Pharyngeal swab ABPC 10 days Cure
12b 15 years 1 Sepsis ? pneumonia Blood PAPM/BP one shot Dead
ABPC ampicillin, CEZ cefazolin, IPM/CS imipenem/cilastatin sodium, PAPM/BP panipenem/betamipron
a Patient was transferred to another hospital for operation
b Patient was transported in a state of shock in the evening by ambulance and was transferred to an advanced emergency medical care center
after receiving basic life support and a single dose of PAPM/BP, but died the following morning. The patient had no underlying disease
associated with increased susceptibility to infection
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Fig. 2 Susceptibilities of S. pyogenes isolates to carbapenems
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Fig. 1 Susceptibilities of Streptococcus pyogenes isolates to penicillins and cephems
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MIC and MBC were 0.008 lg/mL for all strains. The drugs
showing divergent values of the MIC and MBC were:
penicillin G for ﬁve strains, ampicillin for three strains,
cefotaxime for ﬁve strains, and ceftriaxone for eight
strains. A comparison of the sensitivities to these four
drugs revealed that penicillin G had the highest activity,
followed by cefotaxime, ampicillin and ceftriaxone, in that
order. There was no association between emm type and
drug sensitivity.
Discussion
Invasive Group A streptococcal infections include sepsis,
empyema, bone and joint infections, necrotizing fasciitis,
and streptococcal toxic shock syndrome. According to a
number of reports, the estimated incidence of invasive
group A streptococcal infection in children in developed
countries is 1–3 per 100 000 children, and the mortality is
5–20 % [4]. While among all age groups, the incidence is
the highest in elderly people, children younger than 5 years
of age are the next most commonly affected age group [5].
Among reports on invasive group A streptococcal
infections in children, Mulla [6] from the United States
reported the outcomes of 25 children ranging in age from
3 weeks to 17 years with hemolytic streptococcal infec-
tions, who were examined between 1996 and 2000. In
regard to the patients’ age, six children were younger than
1 year old and eight children were 1–4 years of age, with
children younger than 5 years accounting for more than
half of the cases. With regard to the presence of invasive
disease, 18 patients had bacteremia and three had necro-
tizing fasciitis. The mortality was 4.4 %. Henriet et al. [7]
from France reported that, among 28 children examined
between 2000 and 2007, 15 had joint infections, seven had
soft tissue infections, three had pneumonia, and three had
toxic shock syndrome, and the median age was 2.9 years.
Wajima et al. [3]. analyzed the emm types of S. pyog-
enes isolated from patients with invasive group A strep-
tococcal infections diagnosed at medical institutions in
Japan between 2003 and 2006. Among the 74 strains
obtained, many were isolated from patients aged
60–80 years, while only 11 strains (14.9 %) were isolated
from patients younger than 20 years of age. Among the 74
strains, the most prevalent type was emm1 (29 strains;
39.2 %), followed by emm49 (eight strains; 10.8 %) and
emm12 and emm28 (ﬁve strains each; 6.7 %). The emm1
type was the most prevalent, which was consistent with the
results of the present study. In regard to results reported
from Europe and the United States, according to one report,
out of 247 strains, including those isolated from pediatric
patients in Spain between 1998 and 2009, the most pre-
valent emm type was emm1 (60 strains; 24.3 %), followed
by emm3 (21 strains; 8.5 %) and emm4 (14 strains; 5.7 %);
these results indicate a high prevalence of the emm1 type
[8]. In Germany, evaluation of 586 strains revealed that the
most prevalent emm type was emm1 (179 strains; 30.5 %),
accounting for nearly one-third of all the strains, followed
by emm28 (107 strains; 18.3 %) and emm3 (56 strains;
9.6 %) [9]. Similarly, emm1 was also the most commonly
identiﬁed type according to other reports, indicating that
invasive infections are strongly associated with the emm1
type [7, 10]. According to recent studies [11, 12], emm12 is
the most common among the emm types of S. pyogenes
isolated from pharyngitis. However, the frequencies of
emm1 were about half of those in severe infections,
showing differences in distributions of emm types between
pharyngitis and severe infections.
While there are many reports [7, 9, 13, 14] examining
the associations between emm types and pathogenic fac-
tors, such as toxin production and super-antigens, why
emm type 1 is commonly detected in severe infections has
not been elucidated.
Among the drugs used in the drug sensitivity testing,
doripenem exhibited the highest activity, with an MIC of
0.004 lg/mL against all strains. The MIC90 values of
panipenem and meropenem were 0.008 lg/mL, indicating
the superior antibacterial activity of these drugs as com-
pared to that of other agents (MIC90: 0.015–0.03 lg/mL).
The MIC and MBC of carbapenem agents were consistent
for all strains, whereas those of the penicillin agents and
cephem agents were not quite so consistent. No reports
have focused on S. pyogenes exhibiting resistance to pen-
icillin agents, although there are occasional reports of tol-
erance [15–17]; it is considered that, due to the divergence
between MIC and MBC, the strain requires more time to be
killed as compared to other strains, or there is some kind of
mechanism against killing in the bacteria. This phenome-
non is considered to be one of the reasons for the recur-
rence of pharyngitis and tonsillitis caused by S. pyogenes,
even after the administration of effective antimicrobial
agents [18, 19]. Moreover, It is also considered to be one
reason why not a few patients treated with penicillin alone
have poor outcomes in association with the ‘‘inoculum
Table 2 MIC and MBC of S. pyogenes
MIC range MIC90 MBC range MBC90
Penicillin G 0.008 * 0.015 0.015 0.008 * 0.015 0.015
Ampicillin 0.015 * 0.03 0.03 0.015 * 0.03 0.03
Cefotaxime 0.015 * 0.03 0.015 0.015 * 0.03 0.03
Ceftriaxone 0.015 * 0.03 0.03 0.03 * 0.06 0.03
Meropenem 0.008 0.008 0.008 0.008
Panipenem B0.004 * 0.008 0.008 B0.004 * 0.008 0.008
Doripenem B0.004 B0.004 B0.004 B0.004
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effect,’’ a decrease in drug susceptibility when the bacterial
load is large in patients with severe infections [20].
While there are no uniﬁed criteria for tolerance, it is said
that the MIC/MBC ratio is equal to or greater than 16 or 32
[19, 21]. In this study, the maximum MIC/MBC ratio was
twofold, which did not fulﬁll the deﬁnition of tolerance;
however, this phenomenon seems to require attention.
Penicillin agents are considered as the drugs of ﬁrst
choice for invasive streptococcal infections, and concurrent
use of clindamycin is recommended, with the expectation
of its special antimicrobial activities, such as tissue per-
meability, inhibition of toxin production, and promotion of
phagocytic activity. Carbapenem agents have lower MBC
than penicillin agents and, moreover, penicillin is highly
effective in the log phase while its effect decreases in a
steady state [20]. However, there are results, albeit in vitro,
raising the possibility of high efﬁcacy in the early sta-
tionary phase. It is thus considered to be appropriate for the
treatment of severe S. pyogenes infection [22]. As there is
no other study comparing the sensitivities of S. pyogenes to
penicillin agents, carbapenem agents, and cephem agents,
this awaits further basic and clinical investigations.
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